Detecting Alzheimer’s Disease Earlier than Ever.
Non-Invasive, Affordable, and Rapid: The Future of Alzheimer's Detection
Non-Invasive, Affordable, and Rapid: The Future of Alzheimer's Detection
Micron Ophthalmic is dedicated to transforming the diagnostic process and management of Alzheimer's disease. Built on 40 years of groundbreaking research by Dr. Jeffrey N. Weiss, our patented Dynamic Light Spectroscopy (DLS) machine offers the world's first non-invasive, rapid, and cost-effective diagnostic tool for the diagnosis of Alzheimer’s Disease.
And the first tool catching it early enough to form predictions.
Our mission? To pave the way for earlier intervention, better outcomes, and a future free from the uncertainty of late-stage Alzheimer's.
1. We Measure the Retina
The retina, a direct extension of the brain, holds the key to early Alzheimer's detection. Our DLS machine measures retinal protein activity in fewer than 5 seconds.
2. You Receive Results
Immediate, quantitative data on the presence and progression of Alzheimer’s disease, as processed by our integrated software portal will be referred to you.
3. We Empower Treatment
A predictive technology is the first step in crafting accurate and effective medicines and techniques for both preventative and remedial treatments.
Three clinical studies using our twice-patented machine show DLS detects Alzheimer’s early, identifying 4/17 patients up to 1.5 years before a formal diagnosis and accurately identifying 100% of amyloid-positive cases and 83% of negative ones.
When DLS results didn’t align with PET Amyloid Scans, it demonstrated a predictive value; in patients testing positive on the DLS machine but negative on the PET Amyloid Scan, it suggests a future Alzheimer’s diagnosis.
Patient-Centric Care: Seamless, stress-free, and affordable testing for patients at all stages.
Cutting-Edge Science: A diagnostic tool leveraging the connection between the retina and brain.
Global Impact: A potential game-changer for the 44 million new dementia cases diagnosed annually, with actionable impact a possibility.
Our device not only identifies Alzheimer’s earlier than incumbent techniques, but also does so at a fraction of the cost. This innovation holds promise for improving drug trial efficacy, patient outcomes, and healthcare efficiency.
We aim to redefine Alzheimer’s care by enabling early intervention and supporting research into groundbreaking treatments. By detecting the disease earlier, we open the door to more effective therapies and a brighter future for millions of patients - and millions more affected by the disease.
Email us here. LinkedIn.
Schedule time to talk to us here.
